NASDAQ:SCYXSCYNEXIS Stock Price, Forecast & News

$0.88

+0.07 (+8.66 %)

(As of 06/4/2020 01:57 PM ET)

Add

Compare

Today's Range

$0.81

Now: $0.88▼

$0.89

50-Day Range

$0.75

MA: $0.86▼

$1.02

52-Week Range

$0.50

Now: $0.88▼

$1.44

Volume2.17 million shs

Average Volume1.09 million shs

Market Capitalization$86.76 million

P/E RatioN/A

Dividend YieldN/A

Beta1.75

SCYNEXIS, Inc., a biotechnology company, delivers therapies for the treatment fungal infections in the United States. It is developing its lead product candidate, ibrexafungerp, as a novel oral and intravenous drug for the treatment of various fungal infections, including vulvovaginal candidiasis, invasive aspergillosis, invasive candidiasis, and refractory invasive fungal infections. The company develops ibrexafungerp, which has completed Phase 2 clinical trials for the treatment of vulvovaginal candidiasis. It has research collaborations with Merck Sharp & Dohme Corp. and R-Pharm, CJSC to develop and commercialize rights for ibrexafungerp. The company was formerly known as SCYNEXIS Chemistry & Automation, Inc. and changed its name to SCYNEXIS, Inc. in June 2002. SCYNEXIS, Inc. was founded in 1999 and is headquartered in Jersey City, New Jersey.

Beat the Market (BTM) Rank^™

3.5 Analyst's Opinion

Consensus Rating
SCYNEXIS has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 6 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $4.60, SCYNEXIS has a potential upside of 437.1% from its current price of $0.86.
Amount of Analyst Coverage
SCYNEXIS has only been the subject of 4 research reports in the past 90 days.

2.7 Community Rank

Outperform Votes
SCYNEXIS has received 466 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
SCYNEXIS has received 382 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
SCYNEXIS has received 54.95% “outperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about SCYNEXIS and other stocks. Vote “Outperform” if you believe SCYX will outperform the S&P 500 over the long term. Vote “Underperform” if you believe SCYX will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
SCYNEXIS does not currently pay a dividend.
Dividend Growth
SCYNEXIS does not have a long track record of dividend growth.

1.0 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, SCYNEXIS insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 5.56% of the stock of SCYNEXIS is held by insiders.
Percentage Held by Institutions
39.24% of the stock of SCYNEXIS is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6 Earnings and Valuation

Earnings Growth
Earnings for SCYNEXIS are expected to grow in the coming year, from ($0.41) to ($0.19) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of SCYNEXIS is -1.45, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of SCYNEXIS is -1.45, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
SCYNEXIS has a P/B Ratio of 6.59. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Overall Beat the Market Rank^™

1.57 out of 5 stars

Industry, Sector and Symbol

Stock Exchange NASDAQ

Industry Pharmaceutical preparations

Sub-IndustryN/A

SectorMedical

Current SymbolNASDAQ:SCYX

Previous Symbol

CUSIPN/A

CIK1178253

Webwww.scynexis.com

Phone201-884-5485

Debt

Debt-to-Equity Ratio2.23

Current Ratio5.22

Quick Ratio5.22

Price-To-Earnings

Trailing P/E RatioN/A

Forward P/E RatioN/A

P/E GrowthN/A

Sales & Book Value

Annual Sales$120,000.00

Price / Sales722.96

Cash FlowN/A

Price / Cash FlowN/A

Book Value$0.13 per share

Price / Book6.75

Profitability

EPS (Most Recent Fiscal Year)($0.81)

Net Income$-53,710,000.00

Net MarginsN/A

Return on Equity-492.24%

Return on Assets-101.81%

Miscellaneous

Employees27

Outstanding Shares98,810,000

Market Cap$86.76 million

Next Earnings Date8/5/2020 (Estimated)

OptionableOptionable

Receive SCYX News and Ratings via Email

Sign-up to receive the latest news and ratings for SCYX and its competitors with MarketBeat's FREE daily newsletter.

SCYNEXIS (NASDAQ:SCYX) Frequently Asked Questions

How has SCYNEXIS's stock been impacted by COVID-19 (Coronavirus)?

SCYNEXIS's stock was trading at $0.7802 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, SCYX shares have increased by 9.8% and is now trading at $0.8564. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of SCYNEXIS?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for SCYNEXIS in the last year. There are currently 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for SCYNEXIS.

When is SCYNEXIS's next earnings date?

SCYNEXIS is scheduled to release its next quarterly earnings announcement on Wednesday, August 5th 2020. View our earnings forecast for SCYNEXIS.

How were SCYNEXIS's earnings last quarter?

SCYNEXIS Inc (NASDAQ:SCYX) posted its earnings results on Monday, May, 11th. The company reported ($0.07) EPS for the quarter, beating the consensus estimate of ($0.15) by $0.08. View SCYNEXIS's earnings history.

What price target have analysts set for SCYX?

6 Wall Street analysts have issued twelve-month price objectives for SCYNEXIS's stock. Their forecasts range from $3.50 to $6.00. On average, they expect SCYNEXIS's share price to reach $4.60 in the next twelve months. This suggests a possible upside of 437.1% from the stock's current price. View analysts' price targets for SCYNEXIS.

Has SCYNEXIS been receiving favorable news coverage?

News headlines about SCYX stock have trended somewhat negative this week, according to InfoTrie. The research group rates the sentiment of news coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. SCYNEXIS earned a media sentiment score of -1.0 on InfoTrie's scale. They also gave press coverage about the company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an impact on the company's share price in the next few days. View the latest news aboutSCYNEXIS.

Who are some of SCYNEXIS's key competitors?

Some companies that are related to SCYNEXIS include Geron (GERN), Rigel Pharmaceuticals (RIGL), OrganiGram (OGI), TherapeuticsMD (TXMD), Bicycle Therapeutics (BCYC), Verastem (VSTM), Avadel Pharmaceuticals (AVDL), Lannett (LCI), MannKind (MNKD), Verrica Pharmaceuticals (VRCA), Concert Pharmaceuticals (CNCE), AMAG Pharmaceuticals (AMAG), Menlo Therapeutics (MNLO), Ovid Therapeutics (OVID) and Neptune Wellness Solutions (NEPT). View all competitors.

What other stocks do shareholders of SCYNEXIS own?

Based on aggregate information from My MarketBeat watchlists, some companies that other SCYNEXIS investors own include Cerus (CERS), Novavax (NVAX), Inovio Pharmaceuticals (INO), Micron Technology (MU), Matinas BioPharma (MTNB), Verastem (VSTM), Outlook Therapeutics (OTLK), Viking Therapeutics (VKTX), Trevena (TRVN) and T2 Biosystems (TTOO).

Who are SCYNEXIS's key executives?

SCYNEXIS's management team includes the following people:

Dr. Marco Taglietti, CEO, Pres & Director (Age 60, Pay $937.35k)
Mr. Eric Francois, Chief Financial Officer (Age 45, Pay $604.91k)
Mr. David Gonzalez Angulo, Chief Medical Officer (Age 55, Pay $676.13k)
Mr. Scott Sukenick J.D., Gen. Counsel & Corp. Sec. (Age 42)

What is SCYNEXIS's stock symbol?

SCYNEXIS trades on the NASDAQ under the ticker symbol "SCYX."

Who are SCYNEXIS's major shareholders?

SCYNEXIS's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Federated Hermes Inc. (19.37%), BlackRock Inc. (0.98%), Geode Capital Management LLC (0.65%), Connor Clark & Lunn Investment Management Ltd. (0.23%), Creative Planning (0.21%) and Bailard Inc. (0.05%). Company insiders that own SCYNEXIS stock include Gonzalez David Angulo and Marco Taglietti. View institutional ownership trends for SCYNEXIS.

Which institutional investors are selling SCYNEXIS stock?

SCYX stock was sold by a variety of institutional investors in the last quarter, including Bailard Inc., and Squarepoint Ops LLC. View insider buying and selling activity for SCYNEXIS.

Which institutional investors are buying SCYNEXIS stock?

SCYX stock was acquired by a variety of institutional investors in the last quarter, including Federated Hermes Inc., Connor Clark & Lunn Investment Management Ltd., Geode Capital Management LLC, BlackRock Inc., Creative Planning, and HighMark Wealth Management LLC. Company insiders that have bought SCYNEXIS stock in the last two years include Gonzalez David Angulo, and Marco Taglietti. View insider buying and selling activity for SCYNEXIS.

How do I buy shares of SCYNEXIS?

Shares of SCYX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is SCYNEXIS's stock price today?

One share of SCYX stock can currently be purchased for approximately $0.86.

How big of a company is SCYNEXIS?

SCYNEXIS has a market capitalization of $84.62 million and generates $120,000.00 in revenue each year. The company earns $-53,710,000.00 in net income (profit) each year or ($0.81) on an earnings per share basis. SCYNEXIS employs 27 workers across the globe.

What is SCYNEXIS's official website?

The official website for SCYNEXIS is www.scynexis.com.

How can I contact SCYNEXIS?

SCYNEXIS's mailing address is 1 EVERTRUST PLAZA 13TH FLOOR, JERSEY CITY NJ, 07302. The company can be reached via phone at 201-884-5485 or via email at [email protected]

This page was last updated on 6/4/2020 by MarketBeat.com Staff